Regeneron Pharmaceuticals, Inc. faces challenges with Eylea sales but sees growth from Dupixent and obesity drugs. Click for my updated look at REGN.

Analysts have recently evaluated Regeneron Pharmaceuticals and provided 12-month price targets. The average target is $769.35, accompanied by a high estimate of $975.00 and a low estimate of $547.00.

Regeneron Pharmaceuticals sees strength in Dupixent, oncology gains, and major buybacks despite setbacks. Find out why REGN ...

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the 11 best debt-free stocks to invest in right now. The company secured accelerated FDA approval for Lynozyfic (linvoseltamab-gcpt) on July 2, ...

On Friday, RBC Capital Markets downgraded Regeneron (NASDAQ: REGN) Pharmaceuticals’ shares, moving the rating from Outperform to Sector Perform.The firm also significantly reduced the price ...

Regeneron’s stock has experienced a significant decline, dropping 55% since its peak in August 2024, while the S&P 500 index has risen by 5% during the same period.

On Wednesday, TD Cowen adjusted its outlook on Regeneron Pharmaceuticals, with analyst Tyler Van Buren revising the price target to $1,030 from the previous $1,230. Despite the reduction, the firm ...

This was the stock's fourth consecutive day of gains.

Investing.com - TD Cowen has reiterated a Buy rating and $800.00 price target on Regeneron Pharmaceuticals (NASDAQ: REGN), a prominent biotech player with a $58.1 billion market cap, following FDA ...

REGN stock dropped 57.9% from a high of $28.60 on 2 May 2007 to $12.05 on 11 March 2009, in comparison to a peak-to-trough fall of 56.8% for the S&P 500; ...